H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The firm expects veligrotug to meet the endpoints in chronic thyroid eye given that Tepezza demonstrated efficacy in chronic TED treatment. It thinks veligrotug will show at least comparable efficacy to Tepezza.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.